The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-(4,4,4-trifluorobut-2-enoyl)piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one ID: ALA5277376
Max Phase: Preclinical
Molecular Formula: C28H32F3N7O2
Molecular Weight: 555.61
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(C/C=C/C(F)(F)F)CC4)cn3)nc2n(C2CCCC2)c1=O
Standard InChI: InChI=1S/C28H32F3N7O2/c1-18-22-17-33-27(35-25(22)38(20-6-3-4-7-20)26(40)24(18)19(2)39)34-23-9-8-21(16-32-23)37-14-12-36(13-15-37)11-5-10-28(29,30)31/h5,8-10,16-17,20H,3-4,6-7,11-15H2,1-2H3,(H,32,33,34,35)/b10-5+
Standard InChI Key: ZIJYDOFMALQXKA-BJMVGYQFSA-N
Molfile:
RDKit 2D
40 44 0 0 0 0 0 0 0 0999 V2000
-5.7358 1.8903 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.0342 2.3243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.3076 1.9337 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6060 2.3676 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.8794 1.9770 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.8495 1.1485 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1236 0.7629 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4189 1.1917 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.4416 2.0163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1712 2.4079 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6923 0.8010 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0161 1.2320 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7456 0.8468 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.7646 0.0177 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0562 -0.4131 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6661 -0.0235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4896 -0.3759 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.1930 0.0550 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1689 0.8843 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.8727 1.3155 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6002 0.9259 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6243 0.0966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9208 -0.3429 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.3479 -0.3005 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.0583 0.1364 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.0343 0.9657 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3041 1.3580 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7364 1.3988 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7125 2.2234 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4626 1.0073 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.7833 -0.2553 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.3718 -1.1251 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7168 -1.6289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9917 -2.4079 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8163 -2.3839 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.0543 -1.5950 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3041 2.1832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.4626 2.2811 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-5.7358 1.0651 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-6.4504 1.4777 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
5 4 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 1 0
9 10 1 0
5 10 1 0
11 8 1 0
12 11 1 0
13 12 2 0
13 14 1 0
15 14 2 0
11 16 2 0
16 15 1 0
17 14 1 0
18 17 1 0
19 18 2 0
19 20 1 0
21 20 2 0
22 21 1 0
18 23 1 0
23 22 2 0
24 22 1 0
24 25 1 0
26 25 1 0
27 26 2 0
27 21 1 0
28 26 1 0
28 29 1 0
28 30 2 0
31 25 2 0
32 24 1 0
32 33 1 0
33 34 1 0
34 35 1 0
35 36 1 0
32 36 1 0
27 37 1 0
1 38 1 0
1 39 1 0
1 40 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 555.61Molecular Weight (Monoisotopic): 555.2570AlogP: 4.80#Rotatable Bonds: 7Polar Surface Area: 96.25Molecular Species: NEUTRALHBA: 9HBD: 1#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 11.34CX Basic pKa: 6.47CX LogP: 4.64CX LogD: 4.59Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.33Np Likeness Score: -1.08
References 1. Fang L, Chu M, Yan C, Liu Y, Zhao Z.. (2023) Palbociclib and Michael-acceptor hybrid compounds as CDK4/6 covalent inhibitors: Improved potency, broad anticancer spectrum and overcoming drug resistance., 84 [PMID:37011445 ] [10.1016/j.bmc.2023.117263 ]